drugset / Trial / NCT02571049

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

NCT02571049

Phase 2 Completed 24 enrolled Dr. Reddy's Laboratories Limited
RandomizedCrossoverDouble-blindTreatment

Summary

Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.

Timeline

Start
2015-09
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sumatriptan Unknown 3 mg Subcutaneous
Subject Sumatriptan Unknown 6 mg Subcutaneous

Indications